NEWS ANALYSIS. Despite the waiver granted by the US, the global system for fighting HIV – which still causes 630,000 deaths a ...

The data cutoff date for the current analysis of the study was August 8, 2024. With 29.1 months of median follow-up, 12% of ...

The head of the U.N. AIDS agency says the number of new HIV infections could jump more than six times by 2029 if American ...

There were smiles on the faces of parents and children as they left the office of Dr. Martie Gravitt, MD, in Mount Gilead on Feb. 11. Parents said those smiles were the result of Gravitt’s purpose of ...

She was active in St Paul’s Lutheran in Gilead. She was a beloved figure at the Wellness ... be made in her memory to the Homeless No More Cat Rescue in Fairbury, NE or the Beatrice Humane Society.

Gilead Sciences handily beat the consensus Wall Street earnings estimate for Q4. The company projects much higher earnings in full-year 2025. Income and value investors could like this biotech ...

Gilead forecasts it will generate between $28.2 billion and $28.6 billion in full-year sales in 2025. The company didn't reveal how the lenacapavir PrEP rollout will play into that total number ...

Feb 11 (Reuters) - Gilead Sciences (GILD.O), opens new tab posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst estimates on Tuesday ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. A key highlight was the robust performance in the HIV and oncology segments ...

Gilead Sciences (NASDAQ:GILD), a major player in the biotechnology sector, reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 11, that topped analysts' consensus estimates.